Investors in young biotechs are faced with a difficult path to returns: public listings are still scarce and pharma buyers hold the negotiating leverage in merger-and-acquisition talks. Nowadays, venture investors have more frequently taken the unusual step of lining up a potential buyer at the time of a company’s launch by selling an option to acquire the start-up for pre-negotiated terms. Such deals may reassure VCs, but they also limit shareholders’ upside if the start-up eventually exceeds expectations.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
